Relmada Therapeutics, Inc Investor Event Transcript, Nov 16, 2026
Relmada Therapeutics, Inc. (RLMD)
Relmada Therapeutics plans a phase three trial of NDV-1, an extended-release form of gencitabine and docetaxel for bladder cancer. The company expects to enroll its first patient within Q1 if the IND clears in January-February. The company reported $202 million of cash and marketable securities, which it said takes it out through 2029. AI summary
Conference Transcript - RLMD 2026-11-16
Farzin Hak, Analyst — Jefferies
Good to go?
Bipin Dalmia, Other
Okay.
Farzin Hak, Analyst — Jefferies
Good morning, everyone. My name is Farzin Haak, one of the biotech analysts at Jefferies. It's my pleasure to introduce Sergio Traversa, BP in Dalmia, and Maggie Shinodia of RealMada. So this is the Fireside Chat format. Maybe to start off, Sergio, can you provide a brief intro to the company? One minute intro, please.
Sergio Traversa, CEO
Sure. Well, thank you, Farzin, and thank you, Jeffrey, all for the invitation to participate in your conference, and Sergio Traversa, the co-founder and CEO of RealMada. And as a quick overview of the company, we have been on NASDAQ since 2019, and originally was born, RealMada is a pure, is a spin-off from Cornell University, as a pure CNS company, Central Nervous System. I've been working in these programs for many years. The CNS is a very attractive space, and we do still have one leg in CNS. But we thought about managing the risk profile. The CNS is well known for being rather risky. And we expanded to a new area a couple of years ago with the acquisition of the rights of a very interesting, It's an attractive product in bladder cancer, NDVO1, from a company in Israel called Trigon, and this clearly has changed quite dramatically the profile of RealMada, and with a clear improvement in the risk management, and NDVO1 is now the short term of the next 12, 18 months focus of the company, and probably also beyond that. The reason is that the risk profile has been lowered and has been managed because the NW1 is a standard-based formulation of two well-known chemotherapies for cancer, gencitabine and docetaxel, and called gendosi. They're already used in bladder cancer. Now, bladder cancer is an interesting area. It's a tumor, but it's usually not lethal. And the treatment is pretty much a chronic treatment that makes the market very attractive, including the number of patients is also very high. And so NDV-1 is an extended release formulation of Gendosi. Gendosi is already used, but because of the complication of the use, you need a specialized pharmacy, and the treatment takes four or five hours in the doctor's office. This is kind of used or restricted to the university and to the, you know, specialized clinic. While 80% of the patient in bladder cancer is treated in the community setting. Now, the extended release formulation, NDVO-1, it changed totally the profile of this treatment. It's administered in, we say, less than 10 minutes. In reality, it's even less than five minutes. In the commercial form, it would be pre-filled syringe. And it will allow the community treatment of the patient with bladder cancer to use this therapy. That is 80% of the patients. So it's a low risk because it's a clinically known entity. We discussed the FDA, the development plan, that is the true indication for intermediate risk. Sorry. Second line, the post-BCG I'm responsive, and that will be the first indication. So the FDA, we agreed on a plan for the development, two nonentities, and an extended release that can be administered in a very easy and fast way. And so that's what we would like to focus the conversation today. I hope I gave you an idea of what Valmada does in two minutes.
Farzin Hak, Analyst — Jefferies
Great. Can you size the two opportunities that you just talked about, the high-risk settings and the intermediate-risk?
Sergio Traversa, CEO
Sure. And one thing that also I would like to mention before I answer your question, we just announced this morning a very important hire for us. We have a new chief development officer that is the clinician that was formerly at Ferry, I can say that it is now public, and he's virtually the father, the clinical father of astiladrin, where he followed the old development and the global approval, the first viral treatment for bladder cancer, and Yorn has worked with Bipin for 10 years at Ferring, and so we are very, very happy that we have a new high profile person will develop this product, and I let Bipin to To answer your question, he was the Global Head of Urology and Uroncology at Ferring.
Bipin Dalmia, Other
Yeah, thanks, Sergio. Thank you, Farzan. So to size the opportunity, if we just take a step back. In the U.S., I'll just focus on the U.S., there's about 85,000 new cases of bladder cancer, non-muscle invasive bladder cancer that's diagnosed each year, bladder cancer. Of those, 75%, so roughly about 65,000 new patients are diagnosed each year, but because it's a non-lethal cancer in the short term, the prevalent pool is about 600,000. It's a very large patient population, of which about 40% are high-risk, and BCG is used, and then you have BCG unresponsive. So in the BCG unresponsive setting, there's roughly about 16,000 patients. And that's where all the activity is. There are four drugs approved now in the BCGN responsive setting, addressing those 16,000 patients. However, the efficacy of those drugs is... It is limited. And this second-line setting that we are going after, and third-line, because our clinical study is for both second- and third-line setting, that's a growing population. And the estimate we have is about 12,000 patients will fail the first-line BCG-unresponsive setting and go on an annual basis to second-line. But the drug itself, that's our registrational study, and then for the intermediate risk, which is a very recurrent population, that's about 60,000. So our registrational studies will address 12,000 patients in the second line, third line setting, and about 60,000 patients in the intermediate risk setting.
Farzin Hak, Analyst — Jefferies
Makes sense. So the NGIN is developing this non-viral immunotherapy angle, and then you have TYRA, which is also developing an oral therapy. So where does NVIDIA-01, you have a chemo regimen, so that's used primarily in the community settings, I would imagine. And then, like, so basically what would you need to see to basically fit in the treatment landscape?
Sergio Traversa, CEO
Right, I like BBMs, so this one too is.
Bipin Dalmia, Other
Yeah, so in oncology... Everything starts with efficacy, right? So you have to have an efficacious drug. But efficacy is a necessary component for success, but it's not sufficient for success. And with the explosion of drug development and non-muscle invasive bladder cancer... People are looking at the total product profile. They're looking for efficacy without paying a cost on toxicity or convenience. So you need that balanced profile. So what gives us confidence with the NDVO1 profile, and you've seen that in our phase two data, which we can describe, is we have very high and durable response rates without Sacrificing or trading off convenience or tolerability. So it's a very tolerable drug, giving very high efficacy in a drug format that's very easy to use, that opens up the very large community. 80% of patients are treated in the community setting. The two drugs you mentioned, they will have their own efficacy. Based on the data we've seen, I think the efficacy is limited for one of them, and the other one, it's early days, but we don't want to comment too much on other people's drugs, okay?
Farzin Hak, Analyst — Jefferies
Good. I want to touch on the CMC aspect, because that's what is really getting the phase three start. So the phase two product was, you needed like 120 degree centigrade sterilization, and now you're evaluating two different processes. So what are those, and what is the key criteria for choosing between them? Because DOSI has this thermal sensitivity issue that we are aware of.
Sergio Traversa, CEO
Well, thank you, Francine. You may imagine I was expecting, we were expecting that answer. Let me try to address it. CMC manufacturing, it is a very important piece of the whole story because this is an extended formulation of two known chemotherapies, and it was a little bit more complicated than we thought about making it. And the reason being that usually when you acquire a program, you do a technology transfer, right? The product is made somewhere else. You transfer the technology to another manufacturer or another country and so on. This one was not the case for NDVO-1. NDVO-1 in Phase 2 has been made in the pharmacy of the clinic and is used right away. So that allowed that you can sterilize it with the autocloud because there is no need for long-term stability. To make a product that is commercially valuable and can be scaled up and accepted by the FDA, we had to literally invent a brand-new development manufacturing process to make exactly the same process, but in a way that is accepted by the FDA and can be scaled up for commercial. So that was the challenge that we had to face, and whoever is familiar with CMC, it takes time, right? It's usually the... Not many drug has failed for CMC issues, but it takes time to make the process effective and GMP that is accepted by the FDA. So we had a little delay in the middle of the process. The first time that we tried it, and we tried with the technology to sterilize the product. It was involved with moderate heat, and that worked, but didn't work too well. So we take a step back. We redesigned the process that now has been tested, And we have two different efforts. One is made in the U.S., and the other one, as a backup, has been made in Israel by a company called Sinai. You were asking what the difference between the two. The Pyramal in the U.S. effort is produced with two different vials, one containing gencitabine and one containing docetaxa. They are mixed at the bedside of the patients. The effort in Israel, they use a completely different way to sterilize it, that it does not heat, and it is used like acetone as a solvent, and I don't want to go too much in detail because it gets complicated, but the big difference is that using that process, being able to prepare a vial that is already with a mix, and so that can be easily transformed in a pre-filled syringe, and clearly, if the effort of the Israeli company will be successful, It's going to be easier. That would be the criteria to decide which one of the two processes would file the IND. So having a pre-mixed vial is an advantage. It takes one step away.
Farzin Hak, Analyst — Jefferies
So it's a new process. Do you still need to collect bridging data, essentially, to see how the release kinetics works and also the exposure time and the 10-day slow release profile?
Sergio Traversa, CEO
Yeah, that's a good question for Zin. The answer is no, because this is a 502 process, and so it does not really require to have a phase two to get into phase three. However, since we have good phase three data, we have experience in well over 500 treatment, we use them as a support, and we do have some comparison data. Specifically, we have in vitro release, and the product has to be the same with the same in vitro release, and we do have the composition of the product is exactly the same. And the doses of the gencitabine and docetax are also the same. So that is well enough to support an IND for a Phase III filing.
Farzin Hak, Analyst — Jefferies
And for those of us that are concerned about the timeline shift, potentially, what's actually left to get the IND filed? Like you said, nine weeks of stability data that's within FDA requirements, but what else is the gating item to actually file?
Sergio Traversa, CEO
Well, the rest is writing up the IND that has been in the process for a while. Nothing is easy in this business. I would say that preparing an IND and filling in what the FDA requirements are is not the most challenging of the process. We have a very good group of people that is doing that. And I would say the stability data is the one that is still the one that we are waiting for.
Farzin Hak, Analyst — Jefferies
So you need beyond nine weeks?
Sergio Traversa, CEO
For the requirement for the FDA, 30 days is enough. Clearly, the more you have, the better, right? But for the FDA, the requirement is 30 days only.
Farzin Hak, Analyst — Jefferies
And for data timing, so you said the first patient is going to be dosed in one queue, and the IND typically will take 30 to 45 days, depending on the holiday season. So how fast can you reengage the sites, actually, that you already have in mind, to clear and then start dosing patients?
Sergio Traversa, CEO
Sure. Well, we had a few months of time to do that. So all the sites, most of the sites, about 60, they've already been engaged. The contracts are already prepared, and we've been in discussion with them. So clearly you need enough IND cleared by the FDA for the IRB of the single sites to approve the first patient in. But most of the work has already been done. So it's just a question. I'll get the IND clear and finalize the IMB RAB approval. That will translate in a few weeks. So if we get the IND cleared in the January-February time frame, I would say within the Q1 we can enroll the first patient.
Farzin Hak, Analyst — Jefferies
And for data timing, like, when would you see the first interpretable, like, efficacy? Like, would you do a three-month cut or a six-month cut, and how many patients would make sense to do it?
Sergio Traversa, CEO
You want to take that? Yeah.
Bipin Dalmia, Other
Yeah, yeah. So our primary endpoint is what is known as CR at any time, which is you can have a response at either three months, or you can, if you don't have a response at three months, you can get reinduced and get a response at six months, and that is called CR at any time. So that's our primary endpoint, so we will wait for six months of data with a sufficient number of patients to be meaningful. So we expect that to be towards the end of next year. Okay.
Farzin Hak, Analyst — Jefferies
And have you had any conversations with the FDA for a potential breakthrough with every designation, or is it difficult because it's a single-site study?
Sergio Traversa, CEO
Yes. I can take that. This is the easy one, so I can take it. Yeah. And we will apply for Fast Track, and we will also apply for Breakthrough, but for Breakthrough, you need data, so it's going to be later on in the time.
Farzin Hak, Analyst — Jefferies
And then on the, you recently showed the 18-month data, so there was two progressors, BCG naïve, like the T1 at entry, and then was basically CR, and then T2A at month 15. So was it due to maintain, like missing the dose in the maintenance? Like what is the real read into the progression as we see the phase 3 data?
Bipin Dalmia, Other
Yeah, yeah. Well, the real reason is cancer, and then cancer progresses. So if you look at progression rates in general in NMI-BC, they're in the 20%, 30% range. So then if you look at studies, larger studies that have reported in BCG-unresponsive and even BCG-naive space, the progression rate over one year ranges from anywhere from 4% to 20%, depending on which study you look at. So that's the expected rate of progression, 4% to 20%. So in our study, we had two patients who progressed at 15 months. Zero progressed in 12 months. Two patients progressed out of 51. So that's a 4% rate, and that rate is expected. And there were some compliance issues, as we mentioned on the call last week. We don't know if that's the exact reason, but maintenance has been shown, proven to be necessary for high-risk patients. But so far, we've got 96% progression for each of them. Which is well in the range of expected outcomes.
Farzin Hak, Analyst — Jefferies
Got it. And then the re-induction, that phase two allowed you to any time, whereas phase three, you basically, well, any time within 12 months. And then phase three, basically, you can only do it at month three. So is that, how are you thinking about the KOL debate? Like, is it a true durable disease control if you have to re-induce? And how much is really... Because the drug works clearly, but does it really matter that when you do it three months or six months?
Bipin Dalmia, Other
Yeah. So, you know, we currently have a market research in the field, and we're asking the question, so the primary endpoint, CR at any point, doesn't really matter to patients. They don't understand it, and most physicians actually don't understand what that means. So the true number that matters is... If I start therapy, am I still disease-free at 12 months? As a patient, if I'm a bladder cancer patient, I want to know, if I start therapy, what are my chances of being disease-free at 12 months? So that is the most important number, and that is 73%. How you get there? Actually, it's less relevant, whether you get there without a re-induction or with a re-induction. You're still on that therapy. So the reason our Phase II allowed for re-induction at any time is because the options in Israel currently are very limited. None of these first-line BCGN-responsive drugs are available in Israel. One drug was recently launched. So that's why the investigator decided to allow re-induction at any time if the patient failed. In our phase 3 study with the FDA, we've agreed to allow re-induction once because patients do have other options at that point. We don't think it will impact ultimate outcomes. We have very few patients, actually, who got re-induced after three months, even in the Israel study. Got it.
Farzin Hak, Analyst — Jefferies
And then on the phase three, you're allowing up to prior, two prior BCG therapies. So it could be Pembro, Aldosterine, Anctiva, like Tara 200, like all of those. So doesn't that potentially enrich it for like more harder to treat patient population?
Bipin Dalmia, Other
Yeah, and by design. So that is exactly our strategy, is that there are four drugs approved in BCG and responsive setting. But the efficacy there is fairly limited. So this 12-month number that I mentioned, we're showing 73% in the same patient population. That number for approved drugs ranges anywhere from 19% to 42%. No one has been able to cross the 50% threshold yet, even the drugs in development. So the chances of failing first-line therapy... It's actually higher than the chances of succeeding with first-line therapy. So by design, we have enriched for patients who have the greatest unmet need, which is a growing population, second line and third line. But it also is important to note that the response rates after each line of therapy will go down. It's a known phenomenon that after each line of therapy, response rates will go down. So our absolute response rate, which is 73% in our phase two, we don't expect the same response rate in the second line and third line setting. So that's one of the things to keep in mind is absolutely our design by intention is to enrich for a sicker population that don't have options today. But we should also note that the response rates, we should not compare it with the first line response rate.
Farzin Hak, Analyst — Jefferies
So, James, doses sequentially in clinic, it gets to, like, 60%, I believe, in the 12 months. So, is your angle essentially, if you get to 60%, is that a good, like, a benchmark, or is the convenience play the more important thing?
Sergio Traversa, CEO
Yeah, you go. You're a commercial experience. Go ahead.
Bipin Dalmia, Other
Yeah, so to put the landscape in context, again, we're talking first-line BCGN responsive setting. In the first-line BCGN responsive, the commercial landscape today ranges from 19% to 42%. And those are the four approved drugs. There are three other approved drugs, but they're all south of 50%. Jim Docey, the 60% number you referred to in literature, that's a Kaplan-Meier estimate of 60%. So the true number could be a little less than that. Kaplan-Meier estimates generally tend to overestimate response rates. But if we can achieve 60%, that's a huge win. Our Phase II number, again, to remind you, is 73% in a very similar patient population. So we expect, because of our sustained release formulation, that the drug exposure is over a period of 10 days. Conventional gemdose has a drug exposure time of about 60 minutes. So you compare 60-minute drug exposure versus up to 10 days, we do expect we will perform better in the first-line setting. But our registration study is second-line or third-line setting. So we would expect, of course, the response rates to be lower than that. There is no benchmark for the second- or third-line setting.
Farzin Hak, Analyst — Jefferies
Right. I was going to say that. Okay. Switching to the intermediate risk setting, so you are starting this Phase 3 without having any benchmark data from Phase 2. So how are we really, what gives the confidence to move directly there, and what is the effect size that you're really powering it for?
Sergio Traversa, CEO
Can I take it?
Bipin Dalmia, Other
Yeah, so if you look at the baseline event rate, there's a couple of studies that you can power off of, but in the intermediate rest setting, It's a highly recurrent disease, so the rate of progression is fairly low in an intermediate risk setting, but the real unmet need is high progression rate. So we're powered off of those two studies. Effect size, we have not disclosed. I don't believe what we've powered off of, but IBCG, there's an international broader cancer group, That has stated that a 10% absolute benefit over the baseline rate would be clinically meaningful. So you can imagine any improvement which is in the 10% over baseline rate would be considered clinically meaningful by the community. By the urology community. Okay.
Sergio Traversa, CEO
And if I may, the CG oncology intermediate data should come up this month, so that would be an educational exercise we see, especially would be interested to see what the observation arm recurrence rate is.
Farzin Hak, Analyst — Jefferies
Right. Is there a, coming back to the manufacturing, is there a technical know-how barrier on how to formulate your drug that generics cannot potentially do?
Sergio Traversa, CEO
Quite a bit, more than one, right? Well, the formulation of the process, it will be patented, and it was try and error, so it takes resources, and it's definitely an expensive exercise, but also there is the, Gendosi is kind of a local delivery, so there is really no bioavailability data you can compare, so it's going to be very challenging for generic to make a copy.
Farzin Hak, Analyst — Jefferies
Okay, and do you know the, what's the loss of exclusivity, like the patent expiration date potentially?
Sergio Traversa, CEO
The patent is 2047, right, Maggot?
Farzin Hak, Analyst — Jefferies
Okay, great. I think we're almost out of time. So what is the cash runway made for Maggot? And the key catalyst that investors should focus on in the next one?
Maged Shenouda, CFO
Sure. So last week we reported $202 million of cash and marketable securities on the books. That will take us out through 2029. And the big catalysts are a completion of the phase three studies. And in the nearer term, we will have data from the BCG unresponsive study near the end of 2027.
Farzin Hak, Analyst — Jefferies
And will you give an update on the enrollment for the intermediate risks, potentially? Thank you so much for your time.
Sergio Traversa, CEO
Thank you, Farzin.